Results 21 to 30 of about 1,831 (125)

Post-Finasteride Syndrome or Pre-Existing Vulnerability? Rethinking Patient Selection. [PDF]

J Cosmet Dermatol
Rivetti N.
europepmc   +3 more sources

Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System. [PDF]

Int J Dermatol
ABSTRACT Background The United States Food and Drug Administration (FDA) approved oral finasteride for androgenetic alopecia. In 2022, approximately 2.6 million U.S. men used it for hair loss and prostate conditions. Post‐finasteride syndrome (PFS), proposed in 2012, involves persistent sexual and neuropsychiatric adverse events (AEs) after cessation ...
Gupta AK, Talukder M, Keene SA, Bamimore MA.   +3 more
europepmc   +2 more sources

Pharmacological Management of Pattern Hair Loss

Indian Journal of Plastic Surgery, 2021
Pattern hair loss (PHL) is a condition that worsens with time and the only way it can be slowed down is with pharmacological intervention. Pharmacological treatments for PHL, from an evidenced-based perspective with respect to safety and efficacy, are ...
Sandeep Suresh Sattur, Indu Sandeep Sattur   +1 more
doaj   +1 more source

US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?

European Urology Open Science, 2023
Finasteride competitively inhibits 5α-reductase (5-AR) isoenzymes, which blocks dihydrotestosterone (DHT) production, thereby reducing DHT. Finasteride is used in the management of benign prostatic hyperplasia (BPH) and androgenic alopecia.
Haidar Al Saffar, Jennifer Xu, Jonathan S. O'Brien, Brian D. Kelly, Declan G. Murphy, Nathan Lawrentschuk   +5 more
doaj   +1 more source

Research Progress on Platelet-Rich Plasma (PRP) in the Treatment of Androgenetic Alopecia. [PDF]

J Cosmet Dermatol
ABSTRACT Background Androgenetic alopecia (AGA) is the most common cause of progressive hair loss, significantly affecting quality of life. Current therapies, such as minoxidil, finasteride, and hair transplantation, show variable efficacy and may be associated with adverse effects.
Zhong Z, Luo L, Zhao L, Yue X, Lu Y.
europepmc   +2 more sources

A Scoping Review of Non-Opioid Therapeutics for Opioid Withdrawal: Translational Relevance to Neonatal Opioid Withdrawal Syndrome (NOWS) Research. [PDF]

Clin Transl Sci
ABSTRACT In the wake of the ongoing opioid epidemic, the incidence of neonatal opioid withdrawal syndrome (NOWS) has surged. While the short‐term effects of NOWS are well‐characterized, long‐term physiological and molecular consequences remain unclear.
Mills-Huffnagle SL, Lowden OM, Sullivan RE, McFadden TE, Nyland JE.   +4 more
europepmc   +2 more sources

Untargeted Metabolomics and Steroid Signatures in Urine of Male Pattern Baldness Patients after Finasteride Treatment for a Year

Metabolites, 2020
Male pattern baldness (MPB) has been associated with dihydrotestosterone (DHT) expression. Finasteride treats MPB by inhibiting 5-alpha reductase and blocking DHT production.
Yu Ra Lee, Eunju Im, Haksoon Kim, Bark Lynn Lew, Woo-Young Sim, Jeongae Lee, Han Bin Oh, Ki Jung Paeng, Jongki Hong, Bong Chul Chung   +9 more
doaj   +1 more source

Finasteride withdrawal induces anxiety‐like behavior and novelty avoidance in adult male rats [PDF]

J Neuroendocrinol
Abstract Finasteride, an inhibitor of the enzyme 5alpha‐reductase, prescribed for benign prostatic hyperplasia and androgenetic alopecia, induces a wide variety of side effects during treatment and upon withdrawal, like sexual dysfunction and cognitive and psychological disorders, inducing the so‐called post‐finasteride syndrome (PFS).
Cioffi L, Diviccaro S, Chrostek G, Severino F, Giatti S, Scheggia D, Melcangi R.   +6 more
europepmc   +2 more sources

Finasteride Use Does Not Lead to Depression or Suicide: Insights From a Large-Scale Cohort Study and Mendelian Randomization Analysis. [PDF]

J Cosmet Dermatol
ABSTRACT Background Finasteride is widely used in clinical practice to treat androgenetic alopecia (AGA). However, its potential role in increasing the risk of depression and suicidal tendencies among users remains a topic of significant controversy. Patients and Methods Five datasets were used as exposures and ten as outcomes. Mendelian randomization (
Wang J, Lin D, Zhao J, Wei S, Wang H, Li W.   +5 more
europepmc   +2 more sources

Efficacy of Hair Mesotherapy With Biomimetic Peptides and Micronutrients in Patients With Androgenetic Alopecia: A Retrospective Observational Study [PDF]

J Cosmet Dermatol
ABSTRACT Background Hair mesotherapy is increasingly used in the management of androgenetic alopecia (AGA), yet standardized treatment protocols and controlled clinical data are limited. Aims This study aimed to evaluate the efficacy and safety of a mesotherapy formulation containing biomimetic peptides, vitamins, and micronutrients in patients with ...
Köse Ö, Borlu M.
europepmc   +2 more sources